Salt Bridge-forming Residues Positioned over Viral Peptides Presented by MHC Class I Impacts T-cell Recognition in a Binding-dependent Manner
Overview
Molecular Biology
Authors
Affiliations
The viral peptides presentation by major histocompatibility complex class I (MHC I) molecules play a pivotal role in T-cell recognition and the subsequent virus clearance. This process is delicately adjusted by the variant residues of MHC I, especially the residues in the peptide binding groove (PBG). In a series of MHC I molecules, a salt bridge is formed above the N-terminus of the peptides. However, the potential impact of the salt bridge on peptide binding and T-cell receptor (TCR) recognition of MHC I, as well as the corresponding molecular basis, are still largely unknown. Herein, we determined the structures of HLA-B*4001 and H-2K in which two different types of salt bridges (Arg62-Glu163 or Arg66-Glu163) across the PBG were observed. Although the two salt bridges led to different conformation shifts of both the MHC I α helix and the peptides, binding of the peptides with the salt bridge residues was relatively conserved. Furthermore, through a series of in vitro and in vivo investigations, we found that MHC I mutations that disrupt the salt bridge alleviate peptide binding and can weaken the TCR recognition of MHC I-peptide complexes. Our study may provide key references for understanding MHC I-restricted peptide recognition by T-cells.
T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots.
Tian J, Shang B, Zhang J, Guo Y, Li M, Hu Y Nat Immunol. 2025; 26(2):265-278.
PMID: 39875585 DOI: 10.1038/s41590-024-02051-0.
Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines.
Yue C, Wang P, Tian J, Gao G, Liu K, Liu W Int J Biol Sci. 2023; 19(13):4052-4060.
PMID: 37705735 PMC: 10496500. DOI: 10.7150/ijbs.80468.
Jackson K, Antunes D, Talukder A, Maleki A, Amagai K, Salmon A PNAS Nexus. 2022; 1(3):pgac124.
PMID: 36003074 PMC: 9391200. DOI: 10.1093/pnasnexus/pgac124.
Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.
Chen Q, Sun T, Jiang C Nanomicro Lett. 2021; 13(1):92.
PMID: 34138315 PMC: 8006526. DOI: 10.1007/s40820-021-00622-6.
Baruah V, Bose S J Med Virol. 2020; 92(5):495-500.
PMID: 32022276 PMC: 7166505. DOI: 10.1002/jmv.25698.